Ventyx Biosciences, Sanofi
Ventyx gets $27 million investment from Sanofi
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target
Ventyx stock climbs 8% on $27M Sanofi investment
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an as-converted price of $3.8243 per common share. Read more here.
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties in connection with product manufacturing, research and ...
FierceBiotech1d
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
GlobalData on MSN1d
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
ENDPOINTS NEWS1d
Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
BioPharma Dive20h
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...
Pharmaceutical Technology18h
“PBMs favour high list prices”- Novo Nordisk CEO targets PBMs in US Senate hearing
Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.
Sanofi gets binding bids for consumer unit: Bloomberg News
Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read ...
Zacks.com on MSN22h
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million ...